Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis

British Journal of Dermatology

Volumn 170, Issue 2, 2014, Pages 415-424

  Van Den Reek, J M P A ^a   Van Lumig P P M ^a   Driessen, R J B ^a   Van De Kerkhof, P C M ^a   Seyger, M M B ^a   Kievit, W ^a   De Jong, E M G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; KAPLAN-MEIER ESTIMATE; LONG-TERM CARE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 84894267847     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12648     Document Type: Article

References (23)

1. Pathirana D, Ormerod AD, Saiag P, et al,. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl. 2): 1-70.
2. Papp KA, Poulin Y, Bissonnette R, et al,. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol 2012; 66: e33-45.
3. Pariser DM, Leonardi CL, Gordon K, et al,. Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis. J Am Acad Dermatol 2012; 67: 245-56.
4. Rustin MH,. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data. Br J Dermatol 2012; 167 (Suppl. 3): 3-11.
5. Reich K, Burden AD, Eaton JN, et al,. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol 2012; 166: 179-88.
6. Garcia-Doval I, Carretero G, Vanaclocha F, et al,. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol 2012; 148: 463-70.
7. Lecluse LL, Naldi L, Stern RS, et al,. National registries of systemic treatment for psoriasis and the European 'Psonet' initiative. Dermatology 2009; 218: 347-56.
8. Burden AD,. Drug survival rates for tumour necrosis factor-alpha antagonists in psoriasis. Br J Dermatol 2011; 164: 940-1.
9. Rustenbach SJ, Heyer K, Reppenhagen K, et al,. [Registry research in dermatology]. Hautarzt 2011; 62: 189-95 (in German).
10. Gniadecki R, Kragballe K, Dam TN, et al,. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011; 164: 1091-6.
11. Esposito M, Gisondi P, Cassano N, et al,. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol 2013; 169: 666-72.
12. Richtlijn psoriasis 2011 [Guidelines psoriasis 2011]. Dutch Society of Dermatology and Venereology. Available at: http://www.huidarts.info/documents/uploaded-file.aspx?id=579 (last accessed 11 November 2013).
13. Puzenat E, Bronsard V, Prey S, et al,. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 2): 10-16.
14. Glintborg B, Ostergaard M, Dreyer L, et al,. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011; 63: 382-90.
15. Saad AA, Ashcroft DM, Watson KD, et al,. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 2009; 11: R52.
16. Leonardi C, Strober B, Gottlieb AB, et al,. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J Drugs Dermatol 2010; 9: 928-37.
17. Brezinski EA, Armstrong AW,. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. PLOS ONE 2012; 7: e33486.
18. Tyring S, Gordon KB, Poulin Y, et al,. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143: 719-26.
19. Petri H, Urquhart J,. Channeling bias in the interpretation of drug effects. Stat Med 1991; 10: 577-81.
20. Yazici H,. Beware of registries for their biases. Bull NYU Hosp Jt Dis 2012; 70: 95-8.
21. Reich K,. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol 2012; 26 (Suppl. 2): 3-11.
22. Armstrong AW, Harskamp CT, Armstrong EJ,. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes 2012; 2: e54.
23. Hercogova J, Ricceri F, Tripo L, et al,. Psoriasis and body mass index. Dermatol Ther 2010; 23: 152-4.